specializes in biotechnology reagents, genomics, proteomics, and biopharmaceutical research companies. He was the founding CEO of Coda Genomics, a synthetic biology and biofuels company. Dr. Molinari is on the biotech screening committee of the Life Science Angels. He served as a genomics affiliate to the Institute for the Future, a Menlo Park-based think tank. He was the co-founding CEO and president of Protogene Laboratories, Inc., and from 1994 to 1996 led that company to become the world's largest supplier of custom DNA before it was acquired by Life Technologies, Inc. (now Invitrogen). He then ran a spin-off of Protogene for several years which developed ink jet technology for custom DNA chips. Prior to Protogene, Dr. Molinari served as a strategic advisor in the startup of Nanogen, Affymetrix, and Sequenom. Earlier, Dr. Molinari served as the founding CEO of Avitech Diagnostics, a company with DNA sequencing and mutation detection technology (which became part of Variagenics, Inc.) and was a consultant specializing in biotechnology at McKinsey & Co. Dr. Molinari has an A.B. and an MBA from Dartmouth College and a Ph.D. in biophysical chemistry from Brown University.
did postdoctoral research in the Department of Biochemistry, University of Oxford, UK, from 1995 to 2000, focusing on the overlap of bioorganic, combinatorial and surface chemistries. From 2000 to 2002 (San Diego, USA), and from 2002 to 2006 (UK) he worked in the biotech industry developing chemical tools for genomics and proteomics. At Retrotope, Dr. Shchepinov has focused on the use of stable isotopes as a fortification of essential nutrients to protect against diseases of aging and age-related oxidative stress. Dr. Shchepinov received his MS in chemistry and biotechnology from the Mendeleev Institute of Chemical Technology, Moscow, USSR, and a PhD in bioorganic chemistry from the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, in 1994.
is a board certified physician in internal medicine and has direct experience in developing and running small and large clinical programs. Until recently, he was Senior Vice President of Medical and Regulatory Affairs at RRD International, LLC. He joined RRD from Intarcia Therapeutics, where he was the Vice President of Regulatory and Quality Affairs and Chief Regulatory Officer. Previously, Dr. Scribner was Chief Regulatory Consultant for Quintiles Consulting, where he developed and wrote numerous NDA, BLA, IND, IDE, 510(k), PMA, and MAA applications. Prior to Quintiles Consulting, Dr. Scribner spent 10 years at FDA, where he held a variety of positions and was involved in reviewing products regulated by the Center for Biologics. Dr. Scribner holds an MD from the University of Colorado College of Medicine, an MBA from the University of Maryland College of Business and Management, and a BA in biology from Grinnell College.
brings to Retrotope over 25 years of operational, financial and capital markets experience in life sciences, software and investment banking. As a partner of FLG Partners, Ms. Rubinstein’s consulting CFO roles have included ArmaGen, EpiBiome, iPierian (acquired by BMS), True North and Tunitas. Ms. Rubinstein has also served as CFO or run finance and administration at public and private companies including PaxVax, Ingenuity Systems (acquired by QIAGEN), Solexa (acquired by Illumina) and ChemoCentryx. Earlier, she served as an investment banker at Lehman Brothers, Scully Brothers & Foss and Merrill Lynch Capital Markets. Ms. Rubinstein holds BA and MA degrees in Economics from UCLA.
brings to Retrotope over 30 years of experience in developing pharmaceutical products. She has served in a number of senior leadership roles in product development, resulting in asset advancement from research through clinical trials and approvals. Roles included VP of Operations at Signature Therapeutics, Senior VP of Development at Durect Corporation, Head of Development, Vascular Therapeutics, Head of Program Management and Research Scientist at ALZA Corporation. As the founder and President of VSI Development consulting firm, Ms. Magruder has provided support to both large and small companies since 2004 in various aspects of product development, including portfolio analysis, program management, clinical, regulatory and technical development. Ms. Magruder is an inventor on over 50 patents, and holds an MBA from Santa Clara University and a B.S. in Animal Science from the University of California Davis.
has nearly 27 years of experience in pharmaceutical development, solving challenging technical problems and managing complex bioanalytical, analytical, quality, and manufacturing activities. Prior to joining Retrotope, he served as an independent consultant with several clients in the Bay Area, including Raptor Pharmaceuticals, Hyperion Pharmaceuticals, and Gilead Sciences. In his previous career, he worked as a consultant, senior scientist or technical manager, in both laboratory-oriented and non-laboratory roles, for a number of different development-stage and commercial-stage biopharmaceutical enterprises, including Amgen, Sarepta Therapeutics, Poniard Pharmaceuticals, Corus Pharma, QLT, CTI BioPharma, and Novartis. He received an MS degree in Physical Chemistry from NDSU, and a BS in Chemistry from SUNY Albany.
has twenty years of experience managing global Phase I to Phase IV clinical studies focusing on various indications. Prior to joining Retrotope, Mr. Heerinckx served as Associate Director of Clinical Operations at Theravance for three years, where he lead the anti-infectious disease program overseeing a global Phase 3 study in treatment of bacteremia with an IV antibiotic drug. Prior, Mr. Heerinckx lead a clinical operations team at Anacor Pharmaceuticals overseeing studies in support of the development of three molecules. M. Heerinckx worked extensively on Phase 3 studies in the treatment of onychomycosis with a topical drug, and Phase 2 studies in the treatment of psoriasis and atopic dermatitis with a topical drug. Prior, Mr. Heerinckx worked at ARYx Therapeutics as Sr. Clinical Program Manager for three years where he managed a large global Phase 2 clinical study of anti-arrhythmic drug with 70 sites in four countries. Mr. Heerinckx also held various positions in clinical research at Scios, Inc. for nearly 10 years, where he managed and planned several studies from 1996 to 2005. Mr. Heerinckx also worked at Alza as part of the regulatory compliance team. He earned his Pharmacist Degree and Industrial Pharmacist Degree from the University of Leuven in Belgium.
has over twenty five years of experience providing Development and Project Management for various start-up and start-up/large-Pharma ventures. Her areas of expertise include project management, CMC management, regulatory, and clinical operations support. Prior to joining Retrotope, Ms. Schlesinger worked with over 15 companies in various consulting roles, and has served in various positions of project management leadership, process development and engineering for companies including Pearl Therapeutics/AstraZeneca, 3V Biosciences, Incline Therapeutics/The Medicines Co, Medicines360, Medimmune, Medivation/Astellas, Achaogen, Genitope, Nektar/Novartis, Cygnus and others. She holds a BS in Mechanical Engineering from The University of Pittsburgh.
Knobbe Martens Olson & Bear LLP
Wilson Sonsini Goodrich & Rosati